Pharmafile.com’s weekly COVID-19 news round-up
pharmafile | April 14, 2021 | News story | Research and Development | COVID-19, COVID-19 vaccine, covid 19 news, covid-19 news, pharma, pharma news
The past week has seen plenty of good and bad COVID-19 vaccine news; the EMA and CDC have launched investigations into J&J’s COVID-19 shot amid blood clot fears, while Moderna have published the persistence data of its jab after six months, and a collaboration has been announced to investigate COVID brain fog treatment.
1. Regeneron’s drug cocktail shown to prevent symptomatic COVID-19 – Published 13/04/2021
Regeneron’s REGEN-COV treatment cocktail for COVID-19, a combination between casirivimab and imdevimab, has shown a significant reduction in progression to symptomatic versions of the virus, according to a Phase III trial.
2. Asthma drug Budesonide helps COVID-19 recovery at home – Published 13/04/21
Budesonide, a widely-used asthma drug, is the first treatment to be proven to speed up the recovery of COVID-19 patients who stay at home.
3. EMA launch investigation into J&J’s COVID-19 vaccine amid US blood clot reports – Published 12/04/21
The EMA is reviewing reports of rare blood clots in four people in the US who received Johnson & Johnson’s COVID-19 vaccine, one of whom has died.
4. Moderna publishes antibody persistence data of COVID-19 vaccine – Published 09/04/21
Moderna have published antibody persistence data out to six months following the second dose of its COVID-19 vaccine (mRNA-1273) in The New England Journal of Medicine this week.
5. Collaboration announced to investigate COVID brain fog treatment – Published 08/04/21
Akili Interactive has announced a collaboration with Weill Cornell Medicine, New York-Presbyterian Hospital and Vanderbilt University Medical Center, to evaluate the Akili digital therapeutic, AKL-T01, as a treatment for patients with cognitive dysfunction following COVID-19, a condition known as “COVID brain fog”.
Related Content
COVID-19 vaccine eligibility creates challenges for UK pharmacies
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Mental health medicine use in England reaches record high, NHSBSA report reveals
According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions …
